Shire and Boston Children's Hospital Enter Into Broad Research Collaboration

 Shire and Boston Children's Hospital Enter Into Broad Research Collaboration

  PR Newswire

  LEXINGTON, Massachusetts, November 20, 2012

LEXINGTON, Massachusetts, November 20, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG) and Boston Children's Hospital today
announced a three-year, broad research collaboration in rare diseases. The
goal of the collaboration is to develop novel therapies to treat a number of
rare pediatric diseases with high unmet medical need, thereby leveraging
Boston Children's research expertise and Shire's development and
commercialization capabilities. The partnership underscores Shire's long-term
commitment to bring innovative therapies to patients with rare diseases

Under the terms of the agreement, Shire will make an initial upfront payment
to Boston Children's and will have the opportunity to fund selected research
programs. The emphasis will be on opportunities that have the potential to
deliver a development candidate in less than three years from project
initiation. Following the completion of these programs, Shire will have an
exclusive option to enter into a licensing agreement for each program. Upon
entering into any subsequent licensing agreement, Boston Children's will be
eligible to receive certain development and commercial milestone payments, as
well as royalties on product sales from Shire. Shire will have the primary
responsibility for any further clinical development and commercialization of
products arising from the collaboration.The agreement, negotiated on the
Boston Children's side by its Technology & Innovation Development Office,
represents a flexible structure that aligns the parties according to their

"As a leader in rare diseases, Shire is pleased to enter into this innovative
collaboration with Boston Children's, which joins together leaders in academia
and industry to advance pioneering research from the lab to the clinic," said
Dr. Philip J. Vickers, Global Head of Research and Development, Shire HGT.
"Shire has a deep commitment to patients with rare diseases, and our
developmental expertise combined with Boston Children's research capabilities
should enable an acceleration of our discovery and development efforts. Our
collaboration with Boston Children's is an ideal example of how we advance
these goals."

"We are excited about the potential that the collaboration with Shire
represents," said Dr. Alan Beggs, Director of the Manton Center for Orphan
Disease Research at Boston Children's. "Boston Children's brings the research
infrastructure to make the foundational discoveries about these diseases and
our clinicians know the patients and their needs. Partnering with Shire's drug
development capabilities represents a powerful combination that we hope will
facilitate the development of new classes of therapy to ultimately benefit

Notes to editors

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of:

  *Behavioral Health and Gastro Intestinal conditions
  *Rare Diseases
  *Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.

About Boston Children's Hospital

Founded in 1869 as a 20-bed hospital for children, Boston Children's Hospital
has been ranked as one of the nation's best pediatric hospitals by U.S.News &
World Report for the past 21 years. Boston Children's is the primary pediatric
teaching hospital of Harvard Medical School and the largest provider of health
care to Massachusetts children. In addition to 396 pediatric and adolescent
inpatient beds and 228 outpatient programs, Boston Children's houses the
world's largest research enterprise based at a pediatric medical center, where
its discoveries benefit both children and adults. More than 1,100 scientists,
including nine members of the National Academy of Sciences, 11 members of the
Institute of Medicine and nine members of the Howard Hughes Medical Institute
comprise Boston Children's research community. For more information about the
hospital visit: .


Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks
or uncertainties materialize, the Company's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, risks associated with: the inherent uncertainty of research, development,
approval, reimbursement, manufacturing and commercialization of the Company's
Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine
products, as well as the ability to secure new products for commercialization
and/or development; government regulation of the Company's products; the
Company's ability to manufacture its products in sufficient quantities to meet
demand; the impact of competitive therapies on the Company's products; the
Company's ability to register, maintain and enforce patents and other
intellectual property rights relating to its products; the Company's ability
to obtain and maintain government and other third-party reimbursement for its
products; and other risks and uncertainties detailed from time to time in the
Company's filings with the Securities and Exchange Commission.

For further information please contact: Shire Investor Relations Eric Rojas +1-781-482-0999Sarah Elton-Farr
+44-1256-894157 Media Jessica Mann (Corporate)
+44-1256-894-280Jessica Cotrone (Human Genetic Therapies)
+1-781-482-9538 Boston Children's Hospital Rob Graham +1-617-919-3110
Press spacebar to pause and continue. Press esc to stop.